Grossman Adam S 4

What Happened
Adam S. Grossman, President, CEO and a director of ADMA BIOLOGICS (ADMA), had 24,793 shares of common stock withheld on February 19, 2026 at $16.32 per share to satisfy $404,622 in mandatory tax withholding related to RSU vesting. This disposition is reported as code F (tax withholding) and is not an open‑market sale.

Key Details

• Transaction date: 2026-02-19; reported on Form 4 filed 2026-02-23.
• Price: $16.32 per share; total value of withheld shares: $404,622.
• Transaction type/code: F — shares withheld to satisfy tax withholding upon RSU vesting (not an open‑market sale).
• Reported direct holdings: filing references 1,007,896 shares of common stock owned by Grossman (per filing footnote).
• Unvested equity (per footnotes): ~1,251,690 unvested RSUs across multiple grants (grants from 2022–2026) that vest quarterly over four years.
• Additional ownership: filing notes shares owned by entities Areth, LLC and Hariden, LLC for which Grossman is a control person/managing member (specific entity holdings not shown here).
• No indication in the provided data that this was a 10b5-1 plan or a late filing flag; this was a routine tax‑withholding settlement.

Context

• Code F (tax withholding) transactions are routine: when RSUs vest, companies often withhold a portion of shares to cover taxes rather than requiring cash. These are not market‑sales and generally do not signal insider sentiment the way open‑market purchases or voluntary sales might.
• The filing shows substantial remaining unvested RSUs and significant reported direct ownership, meaning Grossman retains meaningful exposure to ADMA equity despite the withholding.